RPG Life Sciences Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹212 Cr +16.5% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
RL

RPG Life Sciences Ltd

Q3 FY26Pharmaceuticals & Biotechnology

RPG Life Sciences Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹180Cr
+4% YoY
−1.1% QoQ
Net profit
₹22Cr
−37.1% YoY
−40.5% QoQ
Margin
22%
−6 pp YoY
+1 pp QoQ

Based on RPG Life Sciences Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹2,900
Market cap₹4.6K Cr
P/E39.7

The short version

Revenue from Operations for Q3 FY26 was Rs. 180.0 crore, up from Rs. 172.7 crore in Q3 FY25 (+4.2% YoY). Q3 FY26 Financials vs Q3 FY25 (Page 14):.

From RPG Life Sciences Ltd's Q3 FY26 earnings-call transcript · updated 25 Sept 2026.

Revenue & Sales Performance

  • Revenue from Operations for Q3 FY26 was Rs. 180.0 crore, up from Rs. 172.7 crore in Q3 FY25 (+4.2% YoY). (Page 14)
  • EBITDA for Q3 FY26 was Rs. 43.2 crore, down from Rs. 52.5 crore in Q3 FY25 (-17.7% YoY). (Page 14)
  • PBT for Q3 FY26 was Rs. 37.5 crore, down from Rs. 46.9 crore in Q3 FY25 (-20.0% YoY). (Page 14)
  • PAT for Q3 FY26 was Rs. 27.9 crore, down from Rs. 34.8 crore in Q3 FY25 (-19.8% YoY). (Page 14)
  • Domestic Formulations contributed 71% to total sales in Q3 FY26, International Formulations 18%, APIs 11%. (Page 16)

2 more points from RPG Life Sciences Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what RPG Life Sciences Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Since FY22, Rs. 140 crores capex infused for building a modern plant with approvals from EU, TGA, PMDA, and others. (Page 27)
  • Modernization and capacity expansion underway for Formulations Units 1 and 2 at Ankleshwar. (Page 24)
  • MF2 (Dedicated immunosuppressant facility), MF3, and MF4 multipurpose units are all undergoing modernization and capacity expansion; approvals include WHO GMP, TGA (Australia), PMDA (Japan), etc. (Page 24)
  • State-of-the-art manufacturing capacity operating EU/TGA-approved plant with enhanced capacity for quality and compliance. (Page 22)
  • Business transformation includes multiple infrastructure modernization and capacity expansion projects targeted at improving quality and manufacturing productivity. (Page 10, 9)

2 more points from RPG Life Sciences Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what RPG Life Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what RPG Life Sciences Ltd said on order book & pipeline — free account, 30 seconds.

RPG Life Sciences Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

RPG Life Sciences Ltd Q3 FY26 results — key figures

RPG Life Sciences Ltd Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue180173+4%182-1.1%
Operating profit (EBITDA)4049-18.4%39+2.6%
Operating margin22%28%-6 pp21%+1 pp
Profit before tax2947-38.3%49-40.8%
Net profit (PAT)2235-37.1%37-40.5%
EPS (₹)13.3821.12-36.6%22.28-39.9%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹212 Cr, net profit ₹28 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules (Q3 FY26)

    Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks

  • Wanbury (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Gujarat Themis Biosyn (Q3 FY26)

    43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q3 FY26)

    Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

RPG Life Sciences Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were RPG Life Sciences Ltd Q3 FY26 results?

Revenue from Operations for Q3 FY26 was Rs. 180.0 crore, up from Rs. 172.7 crore in Q3 FY25 (+4.2% YoY). Q3 FY26 Financials vs Q3 FY25 (Page 14):.

What is RPG Life Sciences Ltd share price analysis?

RPG Life Sciences Ltd currently shows a neutral. The stock trades at a P/E of 39.7 with a market cap of ₹4,635 Cr. Investors should review the full earnings analysis for detailed insights.

Is RPG Life Sciences Ltd planning capital expenditure?

Since FY22, Rs. 140 crores capex infused for building a modern plant with approvals from EU, TGA, PMDA, and others.

Keep RPG Life Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.